Overview

Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes

Status:
Completed

Trial end date:
2011-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical trial is to test safety and tolerability of a vaccine targeting Interleukin-1 beta in patients with type 2 diabetes.

Phase:

Phase 1

Details

Lead Sponsor:

Cytos Biotechnology AG